Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LHP588 in P. Gingivalis-Positive Alzheimer's Disease
NCT06847321Phase 2Recruiting
- Sponsor
- Lighthouse Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of COR588 in Alzheimer's disease (AD), sponsored by Lighthouse Pharmaceuticals. Started Feb 2025; status: recruiting.
02
Drugs
COR588
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06847321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847321.